After three years of outstanding gains, the S&P 500 started off strong in 2026 as well. The index climbed another 1.4% in January, despite experiencing a bit of volatility related to President Donald Trump's potential trade policies. But a pair of exchange-traded funds (ETFs) handily outperformed that result in January, and that trend could continue throughout 2026 and beyond. Several catalysts could support the growth of smaller companies with less weight (or no presence at all) in the S&P 500 index, and ...

Group 1 - The Company, Imperial Petroleum Inc., has announced a share repurchase program authorized by its Board of Directors, allowing the repurchase of up to $10,000,000 of its common stock [1] - The shares may be repurchased through open market or privately negotiated transactions, with the program subject to suspension or discontinuation at any time [1] Group 2 - Imperial Petroleum Inc. is a ship-owning company that provides petroleum products, crude oil, and dry bulk seaborne transportation services [2] - The Company currently owns a total of twenty vessels, including seven M.R. product tankers, two suezmax tankers, three handysize drybulk carriers, five supramax drybulk carriers, two kamsarmax drybulk vessels, and one post panamax drybulk carrier, with a total capacity of approximately 1,291,000 deadweight tons (dwt) [2] - The Company has contracted to acquire an additional five handysize drybulk carriers and a product tanker, which will increase its fleet to a total of 26 vessels with an aggregate capacity of about 1.5 million dwt [2] - The common stock and 8.75% Series A Cumulative Redeemable Perpetual Preferred Stock of Imperial Petroleum Inc. are listed on the Nasdaq Capital Market under the symbols "IMPP" and "IMPPP," respectively [2]

Core Viewpoint - NeuroSense Therapeutics has strengthened its global intellectual property portfolio for its lead drug candidate PrimeC by securing an Australian patent, which complements an existing U.S. patent and extends exclusivity through October 2042 [1][2][3]. Group 1: Intellectual Property and Patent Strategy - The Australian Patent Office granted Australian Patent No. 2022370513 for PrimeC, which is a significant addition to NeuroSense's global patent protection strategy [1][2]. - The granted patent in Australia follows the approval of the corresponding U.S. patent (12,097,185), enhancing NeuroSense's exclusivity strategy for PrimeC across key global markets [2][3]. - CEO Alon Ben-Noon emphasized that securing patent protection in Australia is crucial for executing the company's global IP protection strategy for PrimeC, which is essential for long-term value creation [3]. Group 2: Product Development and Clinical Readiness - PrimeC is a proprietary fixed-dose oral therapy combining ciprofloxacin and celecoxib, designed to target multiple disease pathways implicated in ALS and Alzheimer's disease [3][7]. - The formulation of PrimeC allows for consistent exposure across various disease pathways, supporting a multi-target disease-modifying approach [3]. - PrimeC is now Phase 3-ready in ALS, following positive results from the Phase 2b PARADIGM trial and FDA clearance of the pivotal Phase 3 protocol [4]. Group 3: Market Context and Unmet Medical Needs - Neurodegenerative diseases, including ALS and Alzheimer's, represent significant unmet medical needs, with limited effective therapeutic options currently available [5]. - ALS affects over 5,000 people annually in the U.S., with a substantial disease burden estimated at $1 billion per year [8]. - Alzheimer's disease impacts more than 30 million people globally, characterized by memory loss and cognitive decline, with a pressing need for disease-modifying treatments [10].

Group 1 - The Baron Small Cap Fund experienced a decline of 1.56% in Q4 2025, underperforming the Russell 2000 Growth Index, which gained 1.22% during the same period [1] - For the entire year of 2025, the fund returned -0.66%, trailing the index by 13.67 percentage points, indicating weak performance both absolutely and relatively [1] - Large-cap growth stocks continued to lead the market for the third consecutive year, with concentrated leadership observed [1] Group 2 - Neptune Insurance Holdings Inc. (NYSE:NP) was highlighted as a new addition to the Baron Small Cap Fund's portfolio in Q4 2025, being a leading flood insurance provider [2] - As of February 6, 2026, Neptune Insurance Holdings Inc. had a stock price of $23.56 per share, with a one-month return of -9.42% and a 12-month decline of 19.20% [2] - Neptune Insurance Holdings Inc. has a market capitalization of $3.252 billion [2] Group 3 - The Baron Small Cap Fund added one new holding and increased positions in many existing holdings during Q4 2025, while also selling out of three names [3] - The market's factorization and short-term mentality led to significant price swings, with 11 stocks moving +/- 30% in the quarter, allowing the fund to capitalize on both buying and selling opportunities [3] - Throughout the year, the fund invested in 12 new ideas, with half being new to the public markets, reflecting a positive outlook on the return of IPOs as a source of successful investments [3]

Group 1 - The core focus of the articles is on STM's significant role in the aerospace and AI sectors, highlighting its long-term partnership with SpaceX and a new multi-billion-dollar deal with Amazon [1][2][3] - STM has shipped over 5 billion chips to SpaceX in a decade, showcasing its critical contribution to the functionality of Starlink and the increasing demand for advanced electronics as SpaceX accelerates its lunar launch plans [1] - The recent partnership with Amazon's AWS is not just a typical chip contract but an equity-linked agreement that could provide Amazon with nearly a 3% stake in STM, aimed at securing supply for AI data centers [2] Group 2 - STM is evolving from being viewed solely as an automotive chipmaker to a strategic player in multiple high-tech industries, including aerospace and artificial intelligence [3] - Following the announcement of the Amazon deal, STM's stock price increased by over 9% in pre-market trading, indicating positive market sentiment regarding its diversified business model [3] - The company represents a unique investment opportunity, catering to both the ambitions of SpaceX in space exploration and Amazon's growth in AI, suggesting potential for strong returns [4]

A selloff has created an opportunity to own 'one of the most compelling long-term compounders in fintech,' says Citizens JMP. ...

Pulse Biosciences Inc. (NASDAQ:PLSE) stock is trading higher on continued strength after the company on Friday shared clinical data from its nPulse Cardiac Catheter first-in-human feasibility study.The surge comes as the stock gains momentum, while the broader market experienced slight declines, with the Nasdaq down 0.14% and the S&P 500 down 0.05%, indicating that the stock’s movement is largely driven by company-specific news rather than overall market trends.nPulse Cardiac Catheter Shows Promising Result ...

Core Insights - Taiwan Semiconductor Manufacturing Company (TSMC) has achieved a 67.8% stock gain over the past year, driven by the AI boom and demand for advanced chips from major clients like NVIDIA, Broadcom, and Marvell Technology [2][4][10] - TSMC's performance has outpaced the Zacks Computer and Technology sector, which gained 27.9% in the same period, highlighting investor confidence in TSMC's long-term prospects [3][4] Financial Performance - TSMC's revenues for 2025 increased by 35.9% year over year to $122.42 billion, with earnings per share (EPS) rising 51.3% to $10.65, primarily due to strong demand for 3nm and 5nm chips [10][11] - The company anticipates approximately 30% revenue growth in 2026, with a Zacks Consensus Estimate of $158.2 billion, reflecting a year-over-year growth of 29.2% [11] Market Position and Strategy - TSMC is the leader in the global chip foundry market, benefiting from its scale and technology, which positions it as the preferred choice for companies involved in the AI boom [7][8] - The company plans to invest between $52 billion and $56 billion in capital expenditures in 2026 to meet the growing demand for AI chips, focusing on advanced manufacturing processes [9][10] Valuation - Despite its strong performance, TSMC's stock is considered reasonably priced, trading at a forward 12-month price-to-earnings (P/E) multiple of 24.1, lower than the sector average of 25.93 [12][15] - Compared to other semiconductor companies, TSMC has a lower P/E ratio than Broadcom and NVIDIA, but a higher valuation than Marvell Technology [15] Investment Recommendation - Given TSMC's strong fundamentals, exposure to AI demand, and attractive valuation, it is recommended to buy TSM stock at this time [16]

A Minneapolis mother of two thought her family was making steady progress, until a single financial decision quietly blew a hole in their budget. Her husband refinanced their car to pull out $3,000 in cash and the move left them stuck with a crushing 25% annual percentage rate. The caller, Cathy, shared her story on “The Ramsey Show” with hosts George Kamel and Ken Coleman. What started as an attempt to cover short-term expenses quickly turned into a long-term financial problem that now threatens to snowb ...

Kyndryl Holdings, Inc. (KD) came out with quarterly earnings of $0.52 per share, missing the Zacks Consensus Estimate of $0.6 per share. This compares to earnings of $0.51 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -12.85%. A quarter ago, it was expected that this company would post earnings of $0.35 per share when it actually produced earnings of $0.38, delivering a surprise of +8.57%.Over the last four quarters, the com ...